Analytical Data
-
Gene name
p73 beta
- Application
-
Alternative Names
P73
-
Species
Human
-
Source
Baculovirus
-
Tag
GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15350-3
-
Expression Region
M1-H476
-
Protein Length
Full Length of Isoform-3
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The p73 protein is a member of the p53 family, which plays a crucial role in regulating cell cycle, apoptosis, and DNA damage response. Unlike its well-known counterpart, p53, which is frequently mutated in various cancers, p73 exists in several isoforms, including alpha, beta, and gamma, with distinct functions. The beta isoform, p73 beta, has garnered attention for its potential role in tumor suppression and its involvement in cellular stress responses. Research indicates that p73 beta can induce cell cycle arrest and apoptosis in response to genotoxic stress, making it a key player in maintaining genomic integrity. Furthermore, unlike p53, p73 beta is less commonly found to be mutated in tumors, suggesting that it might be a more stable option for therapeutic strategies. Studies have also revealed its interactions with numerous cellular proteins, which may influence its functional pathways. As a result, understanding the regulatory mechanisms and signaling pathways associated with p73 beta, as well as exploring its potential as a therapeutic target, is vital for developing innovative cancer treatments. Current research focuses on the expression patterns of p73 beta in various cancer types, its functional dynamics within cellular environments, and the possibility of leveraging its activity to enhance existing cancer therapies or develop novel approaches to combat malignancies where p53 is inactive or mutated.
